Corporate Banner
Satellite Banner
Scientific Community
Become a Member | Sign in
Home>News>This Article

Verisante Technology, Inc. Announces Exclusive Distribution Agreement with BO-Pharma BV

Published: Thursday, September 20, 2012
Last Updated: Thursday, September 20, 2012
Bookmark and Share
Company to Attend 21st Congress of the European Academy of Dermatology in Prague, Czech Republic.

Verisante Technology, Inc. announced that the Company has entered into an exclusive agreement with BO-Pharma BV to distribute Verisante Aura™ in Belgium, the Netherlands and Luxemburg ("Benelux").

"BO-Pharma is the largest independent distributor of medical devices in the Benelux region," said Thomas Braun, President & CEO of Verisante. "With the Benelux market outselling the UK and Germany in some dermatological and skin care devices, our partnership with BO-Pharma provides us a strong foothold in this important region. BO-Pharma will not only distribute Aura™, but can also support technical training and servicing in the region."

BO-Pharma and its affiliate, Bo-Esthetics, currently distribute medical devices for skin care treatments, in addition to other devices for use in dermatological practices for a variety of other medical applications. Bo-Esthetics is a leading dermatology distributor in Benelux, distributing the world's top dermatology brands. Aura™ is a natural addition to the Company's existing product line.

"Impressive clinical study results show that Aura™, through speed and accuracy, is a device that can revolutionize the way skin cancer is diagnosed," said Dr. Henk-Peter Oonk, CEO of BO-Pharma. "The Netherlands has historically been very quick to adopt new, disruptive medical technologies, and we are confident this trend will continue with Aura™."

Last year, Aura™ received the Conformite Europeenne (CE) Mark approval, which is recognized by all the 27 Member States of the EU, including Benelux, which has a total population of over 30 million people, and approximately 1,000 dermatologists serving the region. The CE Mark allows the Company to sell Aura™ in Europe, a $78 billion medical device market.

Verisante Aura™ is indicated for use for the evaluation of skin lesions that may be clinically suspicious for melanoma, squamous cell carcinoma and/or basal cell carcinoma when a medical professional chooses to obtain additional information to rule out one of the above conditions before making a final decision to biopsy. Aura™ is a non-invasive optical system that uses Raman spectroscopy to biochemically analyze the skin, providing immediate and accurate results. The device will help to automate the current process of diagnosis, allowing rapid scanning of the 20 to 40 skin lesions on at-risk individuals, improving patient outcomes and comfort.

Further Information
Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 2,800+ scientific posters on ePosters
  • More than 4,000+ scientific videos on LabTube
  • 35 community eNewsletters

Sign In

Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Scientific News
Closing the Loop on an HIV Escape Mechanism
Research team finds that protein motions regulate virus infectivity.
New Analysis Technique for Chiral Activity in Molecules
Professor Hyunwoo Kim of the Chemistry Department and his research team have developed a technique that can easily analyze the optical activity of charged compounds by using nuclear magnetic resonance (NMR) spectroscopy.
Miniaturizable Magnetic Resonance
Microscopic gem the key to new development in magnetic lab-on-a-chip technology.
“Golden Window” in Deep Brain Imaging Opened
The neuroscience community is saluting the creation of a “Golden Window” for deep brain imaging by researchers at The City College of New York led by biomedical engineer Lingyan Shi.
How Viruses Commandeer Human Proteins
Researchers have produced the first image of an important human protein as it binds with ribonucleic acid (RNA), a discovery that could offer clues to how some viruses, including HIV, control expression of their genetic material.
Human Dark Proteome Initiative Launched
Group to focus on advancing research on intrinsically disordered proteins to better understand catastrophic diseases.
Clearest Ever Images of Enzyme that Plays Key Roles in Aging, Cancer
UCLA-led research on telomerase could lead to new strategies for treating disease
Analyzing Protein Structures in Their Native Environment
Enhanced-sensitivity NMR could reveal new clues to how proteins fold.
Proteins with ALS, Cancer Role Do Not Assume a Regular Shape
Our cells contain proteins, essential to functions like protein creation and DNA repair but also involved in forms of ALS and cancer, that never take a characteristic shape, a new study shows.
Studying Bowel Disease With Raman Spectroscopy
inVia confocal Raman microscope used in the study of various childhood diseases.

Skyscraper Banner
Go to LabTube
Go to eposters
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
2,800+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,000+ scientific videos